Investigational drug · Phase 2
ALG-000184
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis B Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "ALG-000184"
First trial start
2025
Jul 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALG-000184", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ALG-000184" as an intervention, largest first.
- A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)Pivotal-lookingActive, not recruiting
Aligos TherapeuticsIndustry
NCT06963710 · 200 participants (planned) · Start Jul 15, 2025 · Primary completion Mar 2027
Drug: ALG-000184; TDF · For: Chronic Hepatitis B Infection
Sites: Coronado, California; Pasadena, California; Rialto, California · 41 sites in all
- A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB SubjectsPivotal-lookingCompleted
Aligos TherapeuticsIndustry
NCT04536337 · 165 participants · Start Oct 22, 2020 · Primary completion Jun 16, 2025
Drug: ALG-000184; Placebo and 1 more · For: Chronic Hepatitis B
Sites: Fitzroy, Australia; Footscray, Australia; Chongqing, China · 10 sites in all
Aligos TherapeuticsIndustry
NCT07943377 · 55 participants (planned) · Start Dec 14, 2026 · Primary completion Aug 6, 2027
Drug: ALG-000184; Placebo · For: Healthy Participants
Sites: Madison, Wisconsin
- A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy VolunteersActive, not recruiting
Aligos TherapeuticsIndustry
NCT06672900 · 24 participants · Start Jan 9, 2025 · Primary completion Jul 7, 2025
Drug: Carbamazepine; Itraconazole (Sporanox) and 1 more · For: Healthy Volunteer
Sites: Austin, Texas
Aligos TherapeuticsIndustry
NCT07342868 · 20 participants · Start Jan 30, 2026 · Primary completion Aug 19, 2026
Drug: Pevifoscorvir Sodium (ALG-000184) · For: Chronic Hepatitis B Infections
Sites: Orlando, Florida
Aligos TherapeuticsIndustry
NCT07342881 · 12 participants · Start Mar 10, 2026 · Primary completion Jul 29, 2026
Drug: Pevifoscorvir Sodium (ALG-000184) · For: Chronic Hepatitis B Infection
Sites: Orlando, Florida; Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Antiviral profile of hepatitis B virus capsid assembly modulator ALG-001075, the parent of pevifoscorvir sodium.
Debing Y, Vanrusselt H, Liu C, et al. · Antiviral Res 2026
- ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial.
Yuen MF, Agarwal K, Jucov A, et al. · Lancet Gastroenterol Hepatol 2026
- Capsid Assembly Modulators: A Promising Curative Regimen for Chronic Hepatitis B.
Ma C, Zhang X, Chang J, et al. · Curr Med Chem 2026
- A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.
Gane E, Schwabe C, Wu M, et al. · Antivir Ther 2025
- The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075.
Vendeville S, Amblard F, Bassit L, et al. · J Med Chem 2024
Also in development for Chronic Hepatitis B Infection
- TDFPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, Chronic Hepatitis B Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.